Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

AbbVie’s $10.9 billion acquisition of Apogee signals a strategic expansion in immunology, leveraging Apogee’s half-life extension technology to improve dosing frequency for atopic dermatitis treatments. Regulatory dynamics at the FDA are shifting as the agency moves toward a reversion to the mean, correcting previous decisions that derailed therapies like Unicure’s AMT-130 for Huntington’s disease. Despite this return to standard scientific review, concerns persist regarding the influence of political appointees in ongoing regulatory disputes, specifically involving RepliMUNE and Amgen. Meanwhile, the approval of CarsGen’s SatraCell in China marks a significant milestone as the world’s first CAR T cell therapy for solid tumors. While this therapy demonstrates clinical efficacy in treating gastric and GEJ cancers, its reliance on complex preconditioning regimens and the challenges of solid tumor heterogeneity highlight the ongoing hurdles for cell therapy development in non-hematological indications.